971 related articles for article (PubMed ID: 15834857)
21. [A case manifested overlapping neuropathologic features of both progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)].
Inagaki T; Seno HI; Iijima M; Nagai A; Bokura H; Kobayashi S; Wada M; Harada T
No To Shinkei; 1998 Mar; 50(3):263-71. PubMed ID: 9566003
[TBL] [Abstract][Full Text] [Related]
22. Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case.
Mochizuki A; Ueda Y; Komatsuzaki Y; Tsuchiya K; Arai T; Shoji S
Acta Neuropathol; 2003 Jun; 105(6):610-4. PubMed ID: 12669238
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of PSP and MSA: a case report and review of the literature.
Uchikado H; DelleDonne A; Uitti R; Dickson DW
Acta Neuropathol; 2006 Feb; 111(2):186-92. PubMed ID: 16456665
[TBL] [Abstract][Full Text] [Related]
24. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration.
Arai T; Ikeda K; Akiyama H; Nonaka T; Hasegawa M; Ishiguro K; Iritani S; Tsuchiya K; Iseki E; Yagishita S; Oda T; Mochizuki A
Ann Neurol; 2004 Jan; 55(1):72-9. PubMed ID: 14705114
[TBL] [Abstract][Full Text] [Related]
25. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy.
Kertesz A; McMonagle P
J Neurol Sci; 2010 Feb; 289(1-2):138-43. PubMed ID: 19733862
[TBL] [Abstract][Full Text] [Related]
26. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
27. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy.
Josephs KA; Duffy JR
Curr Opin Neurol; 2008 Dec; 21(6):688-92. PubMed ID: 18989114
[TBL] [Abstract][Full Text] [Related]
28. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy.
Soliveri P; Piacentini S; Girotti F
Neurology; 2005 Feb; 64(3):448-53. PubMed ID: 15699373
[TBL] [Abstract][Full Text] [Related]
29. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker].
Urakami K; Nakashima K
Rinsho Shinkeigaku; 2002 Nov; 42(11):1162-4. PubMed ID: 12784694
[TBL] [Abstract][Full Text] [Related]
30. Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.
Tolnay M; Sergeant N; Ghestem A; Chalbot S; De Vos RA; Jansen Steur EN; Probst A; Delacourte A
Acta Neuropathol; 2002 Oct; 104(4):425-34. PubMed ID: 12200631
[TBL] [Abstract][Full Text] [Related]
31. Cerebellar cortical tau pathology in progressive supranuclear palsy and corticobasal degeneration.
Piao YS; Hayashi S; Wakabayashi K; Kakita A; Aida I; Yamada M; Takahashi H
Acta Neuropathol; 2002 May; 103(5):469-74. PubMed ID: 11935262
[TBL] [Abstract][Full Text] [Related]
32. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank.
Josephs KA; Dickson DW
Mov Disord; 2003 Sep; 18(9):1018-26. PubMed ID: 14502669
[TBL] [Abstract][Full Text] [Related]
34. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy.
Tuite PJ; Clark HB; Bergeron C; Bower M; St George-Hyslop P; Mateva V; Anderson J; Knopman DS
Arch Neurol; 2005 Sep; 62(9):1453-7. PubMed ID: 16157754
[TBL] [Abstract][Full Text] [Related]
36. Silver stains distinguish tau-positive structures in corticobasal degeneration/progressive supranuclear palsy and in Alzheimer's disease--comparison between Gallyas and Campbell-Switzer methods.
Uchihara T; Shibuya K; Nakamura A; Yagishita S
Acta Neuropathol; 2005 Mar; 109(3):299-305. PubMed ID: 15619127
[TBL] [Abstract][Full Text] [Related]
37. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
39. Progressive supranuclear palsy with fronto-temporal atrophy and various tau-positive abnormal structures.
Li F; Iseki E; Kosaka K; Nishimura T; Akiyama H; Kato M
Clin Neuropathol; 1996; 15(6):319-23. PubMed ID: 8937777
[TBL] [Abstract][Full Text] [Related]
40. Neuropathology of variants of progressive supranuclear palsy.
Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
